Clinical use of lenvatinib in patients with previous renal and/or hepatic impairment and radioiodine‐refractory differentiated thyroid cancer

Abstract

Lenvatinib is one the most active drugs in radioiodine‐refractory differentiated thyroid cancer (RR‐DTC) such that it has become an important therapeutic tool in tumor control and survival. Renal and hepatic impairments are common comorbidities in cancer patients. Treating these patients is a challenge that requires careful consideration. As a first approach to patients with RR‐DTC and renal or hepatic impairment, Summary of Product Characteristics recommendations for lenvatinib use and dose adjustments should be strictly followed. Close clinical and blood monitoring is the gold standard approach to optimizing lenvatinib's use during the whole course of treatment.

Association Between the XRCC1, GSTM1, and GSTT1 Polymorphisms in Model of Thyroid Cancer: A Meta-Analysis

“…However, several factors have been associated with an increased risk of developing thyroid cancer, including exposure to radiation, metabolic syndrome (characterized by obesity, hypertension, hyperlipidemia, and diabetes), unhealthy diet and lifestyle, and environmental pollution [39][40][41]. Implementing measures to reduce radiation exposure, controlling blood pressure, blood lipid levels, blood sugar levels, and weight, as well as adopting healthier living habits, may help to lower the risk of thyroid cancer [42]. In this study, we utilized data from 12 studies, with sample sizes ranging from 211 to 1124, to investigate the association between different genetic polymorphisms and thyroid cancer susceptibility.…”